CNS Response: The key to informed mental health treatment

Leonard Brandt, Chief Executive Officer

Leonard Brandt co-founded CNS Response (CNSO) of Orange County, CA, in 2000 and is its CEO. In many ways this results from his venture capital investment experience, which taught him of the significant need for technology advancement in mental and addictive medicine and his operational experience in building a company from the ground up. He believes that CNSO will dramatically improve the well being of people suffering from these disorders. Len’s prior experience is extensive in new ventures from both venture capital and operating perspectives. As a General Partner at Norwest Ventures he led the fund’s investment activity throughout the 1980’s in all areas of the healthcare including, biopharmaceutical, healthcare services, medical devices and diagnostics. After that Len turned entrepreneur co-founding Time Segment Publishing and Mill City Ventures Consulting. He co-founded Embro Vascular, the dominant supplier of technology for least-invasive saphenous vein harvesting (heart bypass surgery) now supplied through Boston Scientific (BSX). Len’s involvement with an innovative supplier of neurostimulation lead technology, Micronet Medical, (purchased by Advanced Neuromodulation Systems and then St. Jude Medical (STJ)) refocused his attention on CNS analytics and treatment. Len was educated at the University of Illinois and Harvard. He is expanding his education with, Fatherhood 102, a field educational course begun in January 2004 (girl) after successfully completing Fatherhood for Twin Girls 101 on April 6,1999. He is proud to have passed the challenging prerequisite, Husband 101, on April 5, 1997, but his key advisor has suggested he could benefit from an executive educational refresher course. He is an ex-basketball player, ex-skier, ex-autoracer, ex-touring motorcyclist, ex-golfer, and ex-poker player; however, he is known to still masquerade as a squash player.
lbrandt@cnsresponse.com

George Carpenter, President

George Carpenter is a results-oriented executive with a passion for leading high growth and turnaround companies. As President of CNS Response, Inc., George is leading the commercialization of the company’s patented Referenced-EEG technology for psychiatric medication management. Before joining CNS Response Inc., George ran WorkWell Systems Inc., an international physical medicine firm and 2004 winner of the ABL Innovation in Healthcare Award. From 1990 to 2002, George served as Chairman and CEO of CORE, Inc., (Nasdaq: CORE) after leading the management buyout of this division of Baxter Healthcare. A finalist in the E&Y Entrepreneur of the Year program, Carpenter led CORE to a record of clinical software innovation and business development that, in the words of one Wall Street analyst, "created an industry". CORE was acquired in 2001 by Assurant Inc. George was a Vice President of Operations with Baxter Healthcare before founding CORE. His career began at Inland Steel in manufacturing process control and Sales. Serving on various biomedical advisory and fiduciary boards, he is a frequent speaker and writer on healthcare technology and financing issues. His book "The Shape of Things" (LRP Publications, 2006) focused on the neurochemistry of obesity and its impact on the American workforce. He holds an MBA in Finance from the University of Chicago and a BA with Distinction in International Policy & Law from Dartmouth College.
gcarpenter@cnsresponse.com

Daniel A. Hoffman, M.D., Chief Medical Officer

Daniel Hoffman, MD is a Neuropsychiatrist with over 25 years experience treating general psychiatric conditions such as depression, bipolar disorder and anxiety. He provides the newest advances in diagnosing and treating attentional and learning problems in children and adults. Dr. Hoffman has authored over 40 professional articles, textbook chapters, poster presentations and letters to the editors on various aspects of neuropsychiatry, Quantitative EEG, LORETA, Referenced EEG, advances in medication management, national position papers and standards, Mild Traumatic Brain Injury, neurocognitive effects of Silicone Toxicity, sexual dysfunction and other various topics. Dr. Hoffman has given over 58 major presentations and seminars, including Grand Rounds at Universities and Hospitals, workshops and presentations at national society meeting (such as American Psychiatric Association and American Neuropsychiatric Association), national CME conferences, insurance companies, national professional associations, panel member discussant, and presenter of poster sessions. Dr Hoffman has a Bachelor of Science in Psychology from the University of Michigan, an MD from Wayne State University School of Medicine and conducted his Residency in Psychiatry from the University of Colorado Health Sciences Center.
daniel@hoffmanemail.com

Brad Luce, Vice President of Finance and Controller

Brad Luce was appointed Vice President of Finance and Controller in September 2008. He brings over 21 years of financial experience of which 18 years was spent with large, well known public companies within the medical device industry. Prior to joining CNS Response, Brad served as Vice President of Finance at ev3 Neurovascular/Micro Therapeutics, an $80+ million worldwide leader of medical devices for diagnosis and treatment of vascular disorders. From 1995 to 2005, he held a number of financial positions with VIASYS, a $500+ million global market leader in healthcare technology. In 2003, Brad was appointed to the position of Director of Finance, International Operations for VIASYS (recently purchased by Cardinal Healthcare). While at VIASYS, he also held the position of Group Controller, which included a subsidiary, Nicolet BioMedical, an EEG equipment company. From 1988 to 1995, Brad held a number of financial positions, the most recent being International Financial Planning Manager, for Beckman Coulter, a $2.7+ billion provider of instrument systems and complementary products. Brad began his career as an accountant with C.J. Segerstrom & Sons, a large real estate development company in Southern California. He earned his MBA from Pepperdine University in Malibu, California and his BS in Business Finance/Management from Brigham Young University.
bluce@cnsresponse.com

Mark Desrosiers, Senior Vice President Commercial Operations

Mark Desrosiers brings over 17 years of technology and strategy experience with business-to-business and business-to-consumer organizations. Mr. Desrosiers has extensive experience in applying technology solutions to explore and develop new business opportunities. Prior to joining CNS Response, Mr. Desrosiers was Senior Vice President of Product Development for WorkWell Systems, the leading provider of physical medicine solutions. Prior to joining WorkWell Systems, Mr. Desrosiers served as Vice President of Professional Services for Dimension Data North America and was the Managing Director of Dimension Data’s Healthcare and Pharmaceutical business unit. He focused extensively on advising and delivering innovative technology solutions for leading Fortune 500 companies and other forward thinking businesses. In his role, he was responsible for providing management and leadership to the Healthcare and Pharmaceutical business unit, one of Dimension Data’s fastest growing vertically oriented consulting teams. Leading clients include: The Advisory Board Company, AstraZeneca, Bayer, Health Scribe, Johnson & Johnson, McKesson Corporation, Delta Dental, Group Health Incorporated, WellPoint Health Networks and AARP. Mr. Desrosiers has also held senior-level management positions in a number of healthcare service organizations, including the position of Director of Product Development at MedAmerica, a national medical services organization where he directed application development and business strategy efforts for business-critical clinical and process management initiatives. Mr. Desrosiers graduated from the University of Maine with a B.S. in Marketing Communications, with a concentration in Advertising.
mdesrosiers@cnsresponse.com

Brian MacDonald, Chief Engineer

Prior to receiving his MBA from Wharton in 1990, Brian MacDonald was trained in operations and chemical engineering. He consulted for Deloitte & Touche Management Consulting, KPMG Strategic Services and in private practice. His focus throughout this time was in the area of operations and information systems. He is co-founder of Mill City Venture Development that consulted for the predecessor company to CNS Response. In addition to his work in organizing operations, Mr. MacDonald has led the development of the rEEG^® automated statistical report generator and the CNS Response managed care economic simulation and analysis software.
bmacdonald@cnsresponse.com

Ken Graap, Director of Network Services

Ken Graap is Director of Network Services at CNS Response Inc. As Director of Network Services, Ken develops and oversees outreach and education for professionals interested in applying rEEG in their professional work. Ken comes to CNS Response after serving as the CEO of Virtually Better, Inc. (Decatur, GA). As CEO, he successfully headed the development and marketing of Virtual Reality systems for use in health and health related applications. Ken received his undergraduate degree in Technical Management with a minor in Economics from Regis University, a Masters degree in Education Psychology from the University of Alberta. He completed 4 years of doctoral work in Clinical Psychology from Emory University and a clinical internship at the Atlanta VA. Ken worked for 5 years at Lexicor Medical Technology, a manufacturer of Quantitative EEG equipment. Ken currently resides in Atlanta, GA with his wife, Kay and their 6 year old daughter, Kyra who is in kindergarten. When not working, he enjoys playing golf, outdoor activities, and traveling.
kgraap@cnsresponse.com

Barry Kass, Clinical Liaison, National Business Development

Barry Kass has extensive experience as an officer and consultant to medical technology and pharmaceutical companies. He is the former President and CEO of Braintech, Inc., one of the pioneers in the use of computer based technologies for neurological imaging and functional analysis of brain electrical activity mapping. He has extensive experience working with companies and medical institutions developing and/or commercializing the use of computerized technology in the diagnosis and/or treatment of various disease states, especially those related to central nervous system and behavioral health disorders. In addition, he served as Director of Continuing Education and Development for Northeastern University School of Pharmacy and Health Sciences, and he owned a professional pharmacy in New Jersey. He holds a B.S. degree in pharmacy from Rutgers University, an M.B.A. degree from Fairleigh Dickinson University, and he completed graduate courses in hospital administration at Columbia University Graduate School of Public Health and Administrative Medicine.
bkass@cnsresponse.com

Michael Metzig, Manager of Laboratory Services

Michael Metzig has a thorough knowledge of laboratory testing and laboratory operations working for 10 years with Westcliff Medical Laboratories, Inc, (Southern California's largest independently owned medical laboratory). He started the Client Service Department, headed the Quality Assurance Team, co-chaired the Safety Committee, and was the company's Compliance Officer (writing the corporate compliance manual). He also managed the Phlebotomy Department and wrote the phlebotomy procedure manual. His experience in automated and manual laboratory analysis and CLIA regulations is directly applicable to the rEEG production laboratory.
mmetzig@cnsresponse.com

Mark Schiller, MD

Dr. Schiller is an Assistant Clinical Professor in Psychiatry at UCSF and received his medical and psychiatric training at The University of Chicago, Yale University, and UCSF. He has been involved with business development and strategic relationships for three early stage ventures. He is a frequent speaker on TV and radio and is the author of numerous articles on healthcare economics and policy in his role as President of the Association of American Physicians and Surgeons and as Senior Fellow in Medical Studies at the Pacific Research Institute. Dr. Schiller’s areas of responsibility include research, facets of clinical operations, and business development.
mschiller@cnsresponse.com

Meyer Proler, M.D., President, University Neurodiagnostics

Through his telemedicine practice Dr. Proler is believed to be the largest provider of traditional EEG analysis in the US. Dr. Proler supports the company in providing neurological review and qualification of EEG files prior to rEEG analysis.

SCIENTIFIC AND BUSINESS ADVISORS

Stephen C. Suffin, MD, Advisor & Co-Founder

Stephen Suffin, MD is certified in anatomic and clinical pathology and has published more than 50 scientific papers. He is a former Investigator at the Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases and consultant to the Armed Forces Institute of Pathology before returning to the West Coast to become Medical Director at Upjohn’s Laboratory Procedures. Dr. Suffin has served as a medical director for SmithKline Beecham and Quest Diagnostics for over 20 years. Additionally, Dr. Suffin is a board certified psychiatrist who has served as the medical director of two psychiatric hospitals and as the Chief Medical Officer of CNS Response from its founding in 2000 until 2002.

William E. Bunney, Jr., MD, Advisor

William E. Bunney, Jr., MD is currently Senior Associate Dean for Research and Distinguished Professor, Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine. In addition to his position at the University of California, Irvine, Dr. Bunney has held key appointments with several prominent government institutions and research organizations focused on mental health and behavioral sciences-related issues. Among his affiliations, Dr. Bunney currently serves on the Scientific Advisory Boards of the Harvard International Brain Repository and the World Health Organization (WHO) Expert Panel on Mental Health, was previously the Director of the Federal Treatment, Education and Research Endeavor for Narcotic Addiction and Drug Abuse with the National Institutes of Health, and was elected to the Institute of Medicine of the National Academy of Sciences where he was designated a Lifetime National Associate. Dr. Bunney has also served as President of four research organizations: American College of Neuropsychopharmacology, CINP, West Coast College of Biological Psychiatry, and Psychiatric Research Society. Dr. Bunney received his M.D. from the University of Pennsylvania Medical School and completed his residency in Psychiatry at Yale University School of Medicine. He is the author of more than 390 scientific publications and the editor of seven books.

Maurizio Fava, MD, Advisor

Maurizio Fava, MD is currently Associate Chief of Psychiatry for Clinical Research and Director of the Depression Clinical and Research Program at the Massachusetts General Hospital and Professor of Psychiatry at Harvard Medical School. He has authored or co-authored more than 200 original articles, edited four books, published more than 50 chapters, 200 abstracts and given more than 200 presentations at national or international meetings. He has received several awards during his career and is on the editorial board of four international medical journals. Dr. Fava's prominence in the field is reflected by his role as the co-principal investigator of STAR*D, the largest study ever conducted in the area of depression.

Alan Schatzberg, MD, Advisor

Alan Schatzberg, MD is the Kenneth T. Norris, Jr., Professor and Chairman of the Department of Psychiatry and Behavioral Sciences at Stanford University. He has authored over 500 publications and abstracts, including the Manual of Clinical Psychopharmacology, (fifth edition published in 2005), co-edited the Textbook of Psychopharmacology (third edition 2003) and is Co-Editor-in-Chief of the Journal of Psychiatric Research. Dr. Schatzberg has received numerous awards during his career, including most recently the Distinguished Service in Psychiatry Award from the American College of Psychiatrists and is on the editorial board of several international medical journals. In 2003, he was elected into the Institute of Medicine of the National Academy of Sciences.

Max A. Schneider, MD, Advisor

Max Schneider, MD, Director of Education, Positive Action Center at Chapman Medical Center, Orange, California, is a Fellow and Past President of the American Society of Addiction Medicine (ASAM), a Past Chair of the Board of Directors of the National Council on Alcoholism and Drug Dependence (NCADD), a former consultant to the Drug and Alcohol Advisory Committee of the U.S. Food and Drug Administration and a Certified Medical Review Officer. He currently serves as a Clinical Professor at the University of California at Irvine where he teaches in their Addiction Medicine program which he founded in 1969. Dr. Schneider has produced ten films and five booklets on addiction, In 1956 he was a member of the research team that developed “mouth to mouth” resuscitation that revolutionized the technique of artificial resuscitation. He has received 42 different awards, primarily for his contributions to addiction medicine.

Gregory Vistica, Advisor

Gregory Vistica is the president of Washington Media Group, Inc., a communications firm that specializes in crisis management. He is also a principal with SAIL Venture Partners, an energy/cleantech venture firm. He is an author and former award-winning investigative journalist who has worked as a correspondent for Newsweek, a contributing writer for The New York Times Magazine, a staff writer for The Washington Post, a producer for 60 Minutes II, and a military affairs writer for The San Diego Union-Tribune. Mr. Vistica has been nominated for an Emmy by CBS News and was a finalist for a Pulitzer Prize nominated by the New York Times for his exposing Senator Bob Kerry’s role in a Vietnam massacre. He won a Peabody Award and The George Polk Award for his investigative reporting of the “Tailhook Scandal”.

BOARD OF DIRECTORS

Henry T. Harbin, MD, Director

Dr. Harbin is an accomplished psychiatrist with over 30- years experience in the behavioral health field, Dr. Harbin has served as the CEO of two national behavioral health care companies and has held numerous senior positions in both the public and private mental health sectors. Among his past accomplishments, Dr. Harbin served as Commissioner of the President's New Freedom Commission on Mental Health from 2002 to 2003, chairing the subcommittee for the Interface between Mental Health and General Medicine. In addition to his Federal government experience, Dr. Harbin also spent 10 years in the public mental health system in Maryland, serving as Director of the State Mental Health Authority for three of those years. As the chairman, CEO and President of Magellan Health Services, the country's leading behavioral managed care organization, Dr. Harbin led a company with approximately 6,500 employees and revenues of $1.7 billion. During his tenure from 1998 to 2004, Magellan managed the mental health and substance abuse benefits of approximately 70 million Americans including persons who were insured by private employers, Medicaid and Medicare. Prior to Magellan, Dr. Harbin worked for Green Spring Health Services, Inc., one of the largest managed behavioral health organizations in the country. Dr. Harbin held several executive positions at the company, including five years as its president and CEO. Among his achievements in research, Dr. Harbin was a principal investigator and project director for multiple studies at the University of Maryland's Institute of Psychiatry and Human Behavior, and has served as a reviewer for the American Journal of Psychiatry, Journal of Nervous and Mental Disease, and Hospital & Community Psychiatry. Dr. Harbin has also been published in over 10 peer-reviewed articles.

David B. Jones, Director

David Jones has been a Managing Partner of Odyssey Venture Partners II, L.P. since 2003. From 1997 to 2003, he served as Chairman and CEO of Dartron, Inc., a computer accessories manufacturer. From 1985 to 1997, he was a general partner of InterVen Partners, a venture capital firm with offices in Southern California and Portland, Oregon. From 1979 to 1985, he was President and CEO of First Interstate Capital, Inc., the venture capital affiliate of First Interstate Bancorp. Mr. Jones is a director of Earthanol, Inc. He is a graduate of Dartmouth College and holds a Masters of Business Administration and law degrees from the University of Southern California.

Jerome Vaccaro, M.D., Director

Jerome Vaccaro, M.D., joined the Board of Directors in 2006. Dr. Vaccaro is a Senior Vice President with United Health Group’s Specialized Care Services. He has served in a number of health care executive roles, most recently as Chief Executive Officer of United Behavioral Health, and before that as President and Chief Executive Officer of PacifiCare Behavioral Health (“PBH”). Dr. Vaccaro has also served as Medical Director of PBH (1996-2001), Chief Executive Officer of PacifiCare Dental And Vision (2002-2004), and Senior Vice President for the PacifiCare Specialty Health Division (2002-2004). Dr. Vaccaro has an extensive background in community mental health and public sector work, including editing the textbook, “Practicing Psychiatry in the Community,” which is hailed as the definitive community psychiatry text. Jerry completed medical school and a Psychiatry Residency at the Albert Einstein College of Medicine in New York City. After his training, Jerry served on the full-time faculty of the University of Hawaii (1985-1989) and UCLA (1989-1996) Departments of Psychiatry.